John Hamer - 18 Jun 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ABCL
Reported as of: 18 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2021, 18:39:46 UTC
Next SEC filing: 02 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Tryn Stimart, attorney-in-fact

Key filing fact

John Hamer filed Form 4 for AbCellera Biologics Inc. (ABCL) on 22 Jun 2021.

Key facts

This page summarizes John Hamer's Form 4 filing for AbCellera Biologics Inc. (ABCL).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2021, 18:39.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABCL transaction

Common Shares

Other

Transaction value: $0
Shares: -5,000,000
Change %: -17%
Price: $0.000000
Shares after: 24,105,761
Date: 18 Jun 2021
Ownership: See Footnote
Footnotes: F1, F2

ABCL transaction

Common Shares

Other

Transaction value: $0
Shares: +73,892
Change %
Price: $0.000000
Shares after: 73,892
Date: 18 Jun 2021
Ownership: See Footnote
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.

Footnote F2

These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

Footnote F3

These securities are held by DCVC Bio GP. JNK and ZNM are the managing members of DCVC Bio GP. JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio GP. The Reporting Person is one of the managing members of JNK. The managing members of JNK and ZNM share voting and dispositive power with respect to the securities held by DCVC Bio GP. The Reporting Person disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that he is the beneficial owner of such securities, except to the extent of his indirect pecuniary interest therein, if any, by virtue of his interest in DCVC Bio GP and JNK, as applicable.

SEC remarks

This is one of two Form 4s filed on the date hereof in respect of these securities. The Reporting Persons for the other Form 4 are DCVC Bio, DCVC Bio GP, JNK, ZNM, Matthew Ocko, Zachary Bogue and Kiersten Stead.